Some people show clear Alzheimer’s brain changes yet remain cognitively intact, puzzling researchers who expected memory loss to follow pathology.
Researchers identify a molecular signature distinguishing asymptomatic from symptomatic Alzheimer’s
Scientists at the University of California San Diego analyzed gene activity in thousands of human brain samples using a custom AI method to differentiate healthy aging, symptomatic Alzheimer’s, and the asymptomatic form where plaques and tangles exist without cognitive decline.
They found that brains without symptoms display distinct molecular patterns, including altered activity in genes linked to tau protein buildup and stronger activation of cellular protection mechanisms.
The protein Chromogranin A emerges as a potential regulator of cognitive resilience
Researchers focused on Chromogranin A, hypothesizing it acts like a switch determining whether brain pathology leads to memory loss or gets compensated for.
For more on this story, see UCSD Study Finds Chromogranin A May Protect Brain From Alzheimer’s Symptoms in Some People.
In mouse experiments, disabling this protein resulted in typical Alzheimer’s brain changes but preserved mental performance, with female mice showing even stronger effects — less tau accumulation and more stable nerve cell structures.
Findings suggest the brain has built-in defenses that could reshape treatment approaches
The study indicates natural protective mechanisms may influence Alzheimer’s progression, though researchers stress these are preliminary results requiring further validation in humans.
As one researcher noted, decoding the brain’s own defenses could fundamentally alter how we approach treatment.
What does asymptomatic Alzheimer’s mean?
It refers to individuals who have the characteristic brain changes of Alzheimer’s — such as amyloid plaques and tau tangles — but show no memory or cognitive symptoms.
Why might some people resist symptoms despite brain pathology?
According to the study, differences in gene activity — especially involving Chromogranin A and cellular protection systems — may allow the brain to compensate for Alzheimer’s changes, particularly in women.
